Table 1.
Characteristics of evaluated studies.
| Baseline of participants | Interventions | Outcomes | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trials | Simple size | Eyes | Random method | DM type | Gender | DR stage | Age (yr) | Period | Experimental group | Control group | |
| Bai et al., 2010 (1) [29] | 37 (15/12) | 29/24 | NMT | 2 | (9 M : 6 F)/(7 M : 5 F) | Moderate NPDR | 55 ± 8/50 ± 9 | 12 W | 50 mL huangqi decoction, bid | None | VA |
|
| |||||||||||
| Bai et al., 2010 (2) [29] | 29 (13/16) | 23/30 | NMT | 3 | (4 M : 9 F)/(5 M : 11 F) | Severe NPDR | 54 ± 11/59 ± 9 | 12 W | 50 mL huangqi decoction, bid | None | VA |
|
| |||||||||||
| Gao, 2009 [30] | 60 (30/30) | 60/60 | RNT | 2 | (15 M : 15 F)/(14 M : 16 F) | I–III | 56.33 ± 8.6/54.16 ± 7.1 | 8 W | 300 mL huangqi decoction, bid | 6 g shihuyeguang pill (ingredient not including huangqi), tid | VA |
|
| |||||||||||
| Wu et al., 2009 [31] | 44 (20/24) | 20/24 | Computer | 2 | (11 M : 9 F)/(8 M : 16 F) | NPDR | 55.04 ± 7.05/56.07 ± 6.82 | 12 W | 4 pills of huangqi capsule, tid + 2 pills placobo calcium dobesilate capsule, tid | 4 pills placobo huangqi capsule, tid + 2 pills calcium dobesilate capsule, tid | VA, FBG, HbA1C, RAI |
|
| |||||||||||
| Ling and Xu, 2006 [32] | 51 (30/21) | 55/35 | NMT | 2 | (20 M : 10 F)/(14 M : 7 F) | I–IV | 57.2/56.8 | 12 W | Huangqi decoction, bid | 2 tablets of pancreatic kinionogenase enteric-coated Tablet, tid | VA, FM |
|
| |||||||||||
| Zhou et al., 2007 [33] | 120 (70/50) | 129/91 | NMT | NMT | (30 M : 40 F)/(21 M : 29 F) | NPDR | 53.8/54.7 | 12 W | 1.5 g huangqi capsule, tid | 120 IU pancreatic kinionogenase enteric-coated tablet, tid | VA, TC, TG, PV |
|
| |||||||||||
| Cai et al., 2005 [34] | 60 (30/30) | 60/60 | NMT | 2 | (18 M : 12 F)/(17 M : 13 F) | I–III | 56.3 ± 11.3/60.2 ± 9.2 | 16 W | Huangqi decoction, bid | 10 mL xueshuantong injection, ivgtt, qd | VA |
|
| |||||||||||
| Liang et al., 2008 [35] | 60 (30/30) | 60/60 | NMT | 2 | (12 M : 18 F)/(14 M : 16 F) | NPDR and PDR | 59.6/61.2 | 8 W | Huangqi decoction, bid | 500 mg doxium, bid | VA, FM, TG |
|
| |||||||||||
| Teng, 2004 [36] | 60 (30/30) | 60/60 | RNT | NMT | 24 M : 36 F | NPDR | NMT | 10 Mos | 250 mL huangqi decoction, bid | 500 mg doxium, bid | VA, TC, TG |
|
| |||||||||||
| Li, 2004 [37] | 48 (24/24) | 48/48 | NMT | NMT | (14 M : 10 F)/(13 M : 11 F) | I–III | (58.72 ± 6.74)/(54.81 ± 6.84) | 3 Mos | 100 mL huangqi decoction, bid | 2 tablets of ifrarel, tid | VA, FBG, HbA1C, TC, TG, PV, RAI |
|
| |||||||||||
| Chen et al., 2009 [38] | 46 | 49/41 | NMT | 2 | NMT | NPDR | NMT | 3 Mos | Huangqi decoction, bid | 500 mg calcium dobesilate capsule, bid | VA, FM |
|
| |||||||||||
| Lei et al., 2008 (1) [39] | 68 (34/34) | 34/34 | NMT | NMT | (16 M : 18 F)/(19 M : 15 F) | I–III | 56.4 ± 7.3/57.5 ± 6.6 | 2 Mos | Huangqi decoction, qd | 50 mg aspirin, qd | VA |
|
| |||||||||||
| Lei et al., 2008 (2) [39] | 68 (34/34) | 34/34 | NMT | NMT | (18 M : 16 F)/(19 M : 15 F) | I–III | 59.6 ± 7.7/57.5 ± 6.6 | 2 Mos | Huangqi decoction, qd + 50 mg aspirin, qd | 50 mg aspirin, qd | VA |
|
| |||||||||||
| Xiong et al., 2009 [40] | 40 (20/20) | 32/34 | HN | 2 | (9 M : 11 F)/(10 M : 10 F) | I–III | 45–70/43–70 | 90 D | Huangqi decoction, bid | 500 mg doxium capsule, bid | VA, FM, FBG, HbA1C, PV, RAI |
|
| |||||||||||
| Zhang, 2010 [41] | 46 (23/23) | 23/23 | NMT | NMT | (10 M : 13 F)/(11 M : 12 F) | NMT | 52.12 ± 3.70/55.20 ± 4.11 | 4–8 W | 6 g huangqi pills, bid | Conventional treatment of DM | VA |
|
| |||||||||||
| Zhu et al., 1996 [42] | 30 (15/15) | 30/30 | HN | 2 | (8 M : 7 F)/(7 M : 8 F) | I–III | 56.30 ± 11.30/58.20 ± 9.20 | 6 Mos | 6 pills of huangqi pill, tid | Conventional treatment of DM | VA, FM, TC |
|
| |||||||||||
| Li et al., 1999 [43] | 50 (30/20) | 56/36 | NMT | 1, 2 | NMT | I–V | NMT | 2 Mos | 20 mL huangqi decoction, tid | 80 mg gliclazie tablet, bid | VA, FM, TC, TG, PV |
|
| |||||||||||
| Cui, 2006 [44] | 60 (30/30) | 30/30 | RNT | 2 | (12 M : 18 F)/(13 M : 17 F) | NPDR | 60.25 ± 5.40/58.70 ± 5.75 | 90 D | 1 dosage of huangqi decoction, qd | 100 mg ifrarel, tid, for 20 days, withdraw 10 days and for 3 consecutive courses | VA, FM, FBG |
NMT: not mention it, VA: visual acuity, FM: fundus manifestations, PV: plasma viscosity, RNT: random number table, HN: hospitalization number, (1)(2): 2 individual trials conducted in 1 paper.